1.05  0.175 (20%)		01-30 16:00
Open: 0.8989 High: 1.08 Volume: 173,365		Pre. Close: 0.875 Low: 0.8625 Market Cap: 43(M)

Short term
Mid term
Targets	6-month :	1.46	1-year :	1.7
Resists	First :	1.25	Second :	1.46
Pivot price	1.04
Supports	First :	0.97	Second :	0.8
MAs	MA(5) :	0.95	MA(20) :	1.07
	MA(100) :	2.05	MA(250) :	1.78
MACD	MACD :	-0.2	Signal :	-0.3
%K %D	K(14,3) :	30.6	D(3) :	20.6
RSI	RSI(14): 39.2
52-week	High :	3.42	Low :	0.8

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ANEB ] has closed below upper band by 49.8%. Bollinger Bands are 42.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	1.08 - 1.09	1.09 - 1.09
Low:	0.85 - 0.86	0.86 - 0.86
Close:	1.04 - 1.05	1.05 - 1.06

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

Thu, 29 Jan 2026
Anebulo Pharmaceuticals Announces Final Results of Tender Offer - TradingView

Thu, 29 Jan 2026
Investors tender 4.9M Anebulo shares, only 300,000 accepted at $3.50 - Stock Titan

Tue, 27 Jan 2026
Anebulo Pharmaceuticals Announces Preliminary Tender Offer Results - TradingView

Tue, 27 Jan 2026
Nearly 4.9M shares chase Anebulo’s $3.50 self-tender - Stock Titan

Thu, 22 Jan 2026
How Do Investors Really Feel About Anebulo Pharmaceuticals Inc? - Sahm

Tue, 23 Dec 2025
We're Hopeful That Anebulo Pharmaceuticals (NASDAQ:ANEB) Will Use Its Cash Wisely - simplywall.st

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	41 (M)
Shares Float	3 (M)
Held by Insiders	40.5 (%)
Held by Institutions	54 (%)
Shares Short	69 (K)
Shares Short P.Month	121 (K)

EPS	-0.22
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.23
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-86.2 %
Return on Equity (ttm)	-145.2 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-6 (M)
Levered Free Cash Flow	-3 (M)

PE Ratio	-4.78
PEG Ratio	0
Price to Book value	4.37
Price to Sales	0
Price to Cash Flow	-7.28

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.